Diurnal Group PLC Director Dealings (1273B)

TIDMDNL

RNS Number : 1273B

Diurnal Group PLC

05 January 2018

5 January 2018

Diurnal Group plc

("Diurnal" or the "Company")

Director Dealings

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that Non-Executive Director, John Goddard, has acquired 10,791 recently vested shares at GBP0.05 per share.

As published in the Company's AIM Admission Document, published on 21 December 2015, and in connection with his recruitment, John Goddard was awarded 32,374 ordinary shares of GBP0.05 each for which Mr Goddard will pay the nominal value for each share. The award of shares vest in thirds 18, 24 and 36 months from 24 December 2015, being the date of admission to AIM. There are no other performance criteria.

John Goddard's interest in the Company is now as follows:

 
 Name            Position                   Total number of conditional shares     Total number of ordinary shares now 
                                            now held                               held 
--------------  ------------------------  -------------------------------------  ------------------------------------- 
 John Goddard    Non-Executive Director     10,792                                 37,774 
--------------  ------------------------  -------------------------------------  ------------------------------------- 
 
 
 For further information, please visit www.diurnal.co.uk 
  or contact: 
 
                                           [phone] 
 Diurnal Group plc                          1000 
 Martin Whitaker, Chief Executive 
  Officer 
 Richard Bungay, Chief Financial 
  Officer 
 
 Numis Securities Ltd (Nominated           [phone] 
  Adviser)                                  1000 
 Nominated Adviser: Michael Meade, 
  Paul Gillam, Freddie Barnfield 
 Corporate Broking: James Black 
 
 Panmure Gordon (UK) Limited (Joint        [phone] 
  Broker)                                   2500 
 Corporate Finance: Freddy Crossley 
 Corporate Broking: Tom Salvesen 
 
                                           [phone] 
 FTI Consulting                             1000 
 Simon Conway 
 Victoria Foster Mitchell 
 

Notes to Editors

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk

 
 1     Details of the person discharging managerial 
        responsibilities / person closely associated 
----  ---------------------------------------------------------------- 
 a)    Name                            John Goddard 
----  -----------------------------  --------------------------------- 
 2     Reason for the notification 
----  ---------------------------------------------------------------- 
 a)    Position/status                Non-Executive Director 
----  -----------------------------  --------------------------------- 
 b)    Initial notification           Initial notification 
        /Amendment 
----  -----------------------------  --------------------------------- 
 3     Details of the issuer, emission allowance 
        market participant, auction platform, auctioneer 
        or auction monitor 
----  ---------------------------------------------------------------- 
 a)    Name                           Diurnal Group plc 
----  -----------------------------  --------------------------------- 
 b)    LEI                            213800I2HNUNZN1LDH29 
----  -----------------------------  --------------------------------- 
 4     Details of the transaction(s): section to 
        be repeated for (i) each type of instrument; 
        (ii) each type of transaction; (iii) each 
        date; and (iv) each place where transactions 
        have been conducted 
----  ---------------------------------------------------------------- 
 a)    Description of                 Ordinary shares of 5p each 
        the financial 
        instrument, type 
        of instrument 
---- 
 
       Identification                 GB00BDB6Q760 
        code 
 
 b)    Nature of the                  Purchase of shares 
        transaction 
----  -----------------------------  --------------------------------- 
 c)    Price(s) and volume(s) 
----                                  ---------------  ------------- 
                                       Price(s)         Volume(s) 
----                                  ---------------  ------------- 
    GBP539.55                                           10,791 
   --------------------------------------------------  ------------- 
 
 d)    Aggregated information 
---- 
 
  - Aggregated volume            10,791 
 
  - Price                        GBP539.55 
 
 e)    Date of the transaction        5 January 2018 
----  -----------------------------  --------------------------------- 
 f)    Place of the transaction       London Stock Exchange, AIM 
----  -----------------------------  --------------------------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOALLFLVLTIEIIT

(END) Dow Jones Newswires

January 05, 2018 08:19 ET (13:19 GMT)